ArticleFrontiers in microbiology2025
Identification of linear B-cell epitopes of Senecavirus A VP2 protein using monoclonal antibodies.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Indirect ELISA Using Multi-Antigenic Dominants of VP1, VP2, and VP3 Recombinant Protein to Detect Antibodies Against Senecavirus A in Pigs.Veterinary sciences · 2026Article
- Establishment and Application of a Novel Protein Microarray for Serological Detection and Differentiation of Senecavirus A.Transboundary and emerging diseases · 2026Article
- Structural and epitope characterization of anti-DEFA5 monoclonal antibodies clones 1A8 and 4F5 for inflammatory bowel disease subtype diagnostics.International journal of biological macromolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Senecavirus A (SVA) is an emerging vesicular pathogen in swine with clinical signs similar to those of foot-and-mouth disease, porcine vesicular disease and vesicular stomatitis, making the control of swine vesicular disease outbreaks difficult. Therefore, the development of effective diagnostics and vaccines for SVA has become critical. VP2 is a structural protein that elicits a strong immune response, which positions it a candidate for diagnostic and vaccine development. Methods: In this study, five high-titer monoclonal antibodies (mAbs) were produced using hybridoma technology. Twenty-eight peptides covering the entire VP2 sequence were synthesised by overlapping peptide synthesis, and the positive peptides were screened with the five mAbs by ELISA and Dot-blotting. The peptides were then further truncated to identify the minimal epitope regions based on immunoinformatics analyses. Results: Four mAbs were identified that reacted with peptide 15 and one mAb reacted with peptide 26. Further truncation of these peptides led to the identification of two novel minimal epitopes: 156-NEEQWV-161 and 262-VRPTSPYFN-270. Structural and sequence alignment analyses revealed that epitope 156-NEEQWV-161 is located in the flex-loop region of the VP2, whereas epitope 262-VRPTSPYFN-270 is located in the β-sheet of the VP2. Both epitopes were highly conserved among typical SVA isolates from different countries. Discussion: This study identifies two novel B-cell epitopes on the VP2, contributing to the development of VP2-based diagnostic tools with clinical applications. The findings also provide valuable material for the design of novel vaccines against SVA, offering new insights into the immune response to this pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.